Loading…
Loading…
LQDA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LQDA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LQDA and 80,000+ other tickers.
See exactly how LQDA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LQDA and 80,000+ other tickers.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
On July 13, 2026, Liquidia Corp (LQDA) shares experienced a notable decline of 8.7%, currently priced at $71.22. This price movement comes amidst a 52-week rang
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.